Stockscreener 앱 받기
8.93
6.10%
-0.58
Arcus Biosciences Inc 주식(RCUS)의 최신 뉴스
Arcus Biosciences (NYSE:RCUS) Shares Down 8.6% – Here’s What Happened - Defense World
Arcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Arcus Biosciences’ SWOT analysis: stock’s potential in cancer therapy market By Investing.com - Investing.com Nigeria
BNP Paribas Financial Markets Purchases 9,016 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Deutsche Bank AG Boosts Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences’ SWOT analysis: stock’s potential in cancer therapy market - Investing.com
Arcus Biosciences Announces New Employment Inducement Grants | RCUS Stock News - GuruFocus
Arcus Biosciences Announces New Employment Inducement Grants - Business Wire
Lazard Asset Management LLC Has $93,000 Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Barclays Reaffirms Their Buy Rating on Arcus Biosciences (RCUS) - The Globe and Mail
Recent Investment Analysts’ Ratings Changes for Arcus Biosciences (RCUS) - Defense World
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Bought by Northern Trust Corp - Defense World
Arcus Biosciences Stock May Be The Next To Fail (NYSE:RCUS) - Seeking Alpha
Arcus Biosciences, Inc. (NYSE:RCUS) Analysts Just Slashed This Year's Revenue Estimates By 17% - simplywall.st
Trading (RCUS) With Integrated Risk Controls - news.stocktradersdaily.com
Price T Rowe Associates Inc. MD Sells 6,265 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Morgan Stanley Cuts Arcus Biosciences (NYSE:RCUS) Price Target to $22.00 - Defense World
First Trust Advisors LP Has $264,000 Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Cantor Fitzgerald Has Weak Forecast for RCUS FY2025 Earnings - Defense World
Arcus Biosciences Announces New Employment Inducement Grants | R - GuruFocus
HC Wainwright Predicts Weaker Earnings for Arcus Biosciences - Defense World
Arcus Biosciences (RCUS): Morgan Stanley Lowers Price Target | R - GuruFocus
Wedbush Decreases Earnings Estimates for Arcus Biosciences - Defense World
Raymond James Financial Inc. Makes New Investment in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Morgan Stanley Lowers Price Target on Arcus Biosciences to $22 From $24, Keeps Overweight Rating - marketscreener.com
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates - MSN
Goldman Sachs Adjusts Price Target for Arcus Biosciences (RCUS) - GuruFocus
Goldman Sachs Adjusts Price Target for Arcus Biosciences (RCUS) | RCUS Stock News - GuruFocus
Wells Fargo Adjusts Price Target for Arcus Biosciences (RCUS) to $26 | RCUS Stock News - GuruFocus
Arcus Biosciences First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Arcus Biosciences (RCUS) Receives Adjusted Price Target from Wel - GuruFocus
Arcus Biosciences (NYSE:RCUS) Shares Gap Down on Disappointing Earnings - Defense World
Analyzing Ratios: Arcus Biosciences Inc (RCUS)’s Financial Story Unveiled - DWinneX
European regulators to review Valneva shot; Jazz's stock dips on subpar first-quarter revenue - Endpoints News
Arcus Biosciences, Inc. (NYSE:RCUS) Q1 2025 Earnings Call Transcript - MSN
Arcus Biosciences (RCUS) Receives Adjusted Price Target from Wells Fargo | RCUS Stock News - GuruFocus
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Purchased by Dimensional Fund Advisors LP - Defense World
Arcus Biosciences Q1 2025 Earnings Call Transcript - MarketBeat
Arcus Biosciences Inc (RCUS) Q1 2025 Earnings Call Highlights: Strategic Focus and Financial ... - Yahoo Finance
Arcus Biosciences Inc (RCUS) Q1 2025 Earnings Call Highlights: Strategic Focus and Financial ... By GuruFocus - Investing.com Canada
Arcus Biosciences earnings missed by $0.12, revenue fell short of estimates - Investing.com Canada
Earnings call transcript: Arcus Biosciences Q1 2025 misses earnings estimates - Investing.com
Earnings call transcript: Arcus Biosciences Q1 2025 misses earnings estimates By Investing.com - Investing.com India
Arcus Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Arcus Biosciences (RCUS) Misses Q1 Revenue Expectations, Outlines Future Plans | RCUS Stock News - GuruFocus
Arcus Biosciences Q1 2025 Earnings: EPS Misses at -$1.14, Revenue Falls Short at $28 Million - GuruFocus
Arcus Biosciences Q2 2025 slides: advancing late-stage oncology pipeline with $1B cash - Investing.com Canada
Arcus Cancer Drug Shows Breakthrough 30% Response Rate in Kidney Cancer Trial, Reports Strong Q1 Earnings - Stock Titan
Earnings To Watch: Arcus Biosciences Inc (RCUS) Reports Q1 2025 Result - GuruFocus
Renaissance Technologies LLC Lowers Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences, Inc.'s (NYSE:RCUS) Shares Bounce 33% But Its Business Still Trails The Industry - simplywall.st
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Long Term Trading Analysis for (RCUS) - news.stocktradersdaily.com
1.89%
3.74%
자본화:
|
볼륨(24시간):